Munich, Germany-based radiopharmaceutical company ITM Isotope Technologies has appointed Andrew Cavey as its new chief executive officer.
From the start of September, Dr Cavey will take over from current CEO, Steffen Schuster, who will join ITM's supervisory board.
Dr Cavey brings experience from his roles at Bristol Myers Squibb (NYSE: BMY) and Novartis (NOVN: VX). At Bristol Myers he served as a senior vice president as the company made its entry into radiopharmaceuticals.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze